Mark J Niciu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5082552/publications.pdf

Version: 2024-02-01

71 papers	4,491 citations	87723 38 h-index	106150 65 g-index
75 all docs	75 docs citations	75 times ranked	5971 citing authors

#	Article	IF	Citations
1	Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biological Psychiatry, 2017, 81, 886-897.	0.7	334
2	Do the dissociative side effects of ketamine mediate its antidepressant effects?. Journal of Affective Disorders, 2014, 159, 56-61.	2.0	227
3	NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16720-16725.	3.3	226
4	Overview of glutamatergic neurotransmission in the nervous system. Pharmacology Biochemistry and Behavior, 2012, 100, 656-664.	1.3	224
5	Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. Journal of Psychiatric Research, 2014, 58, 161-166.	1.5	224
6	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Journal of Psychopharmacology, 2015, 29, 596-607.	2.0	175
7	Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Therapeutic Advances in Chronic Disease, 2015, 6, 97-114.	1.1	169
8	The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology, 2018, 235, 1923-1932.	1.5	162
9	PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Research, 2018, 8, 57.	1.1	144
10	Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds. Annual Review of Pharmacology and Toxicology, 2014, 54, 119-139.	4.2	140
11	Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression. Journal of Clinical Psychiatry, 2014, 75, e417-e423.	1.1	120
12	Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. Journal of Neural Transmission, 2014, 121, 907-924.	1.4	115
13	NEUROBIOLOGY OF ANXIOUS DEPRESSION: A REVIEW. Depression and Anxiety, 2013, 30, 374-385.	2.0	96
14	Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. Journal of Affective Disorders, 2017, 218, 195-200.	2.0	94
15	A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders, 2015, 17, 438-443.	1.1	88
16	Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. Journal of Affective Disorders, 2018, 232, 310-315.	2.0	87
17	Effect of Baseline Anxious Depression on Initial and Sustained Antidepressant Response to Ketamine. Journal of Clinical Psychiatry, 2014, 75, e932-e938.	1.1	84
18	Defining anxious depression: a review of the literature. CNS Spectrums, 2013, 18, 252-260.	0.7	83

#	Article	IF	Citations
19	cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. Molecular Psychiatry, 2017, 22, 754-759.	4.1	81
20	Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. Current Neuropharmacology, 2017, 15, 57-70.	1.4	78
21	The role of adipokines in the rapid antidepressant effects of ketamine. Molecular Psychiatry, 2017, 22, 127-133.	4.1	75
22	Developmental changes in the expression of ATP7A during a critical period in postnatal neurodevelopment. Neuroscience, 2006, 139, 947-964.	1.1	72
23	Altered ATP7A expression and other compensatory responses in a murine model of Menkes disease. Neurobiology of Disease, 2007, 27, 278-291.	2.1	67
24	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. Journal of Affective Disorders, 2018, 231, 51-57.	2.0	62
25	A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. Psychopharmacology, 2016, 233, 1119-1130.	1.5	59
26	Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. Journal of Clinical Psychiatry, 2017, 78, 1068-1074.	1.1	55
27	Assessing measures of suicidal ideation in clinical trials with aÂrapid-acting antidepressant. Journal of Psychiatric Research, 2015, 68, 68-73.	1.5	54
28	Decreased Occipital Cortical Glutamate Levels in Response to Successful Cognitive-Behavioral Therapy and Pharmacotherapy for Major Depressive Disorder. Psychotherapy and Psychosomatics, 2014, 83, 298-307.	4.0	53
29	Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder. Journal of Clinical Psychiatry, 2016, 77, 825-831.	1.1	53
30	Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Journal of Affective Disorders, 2017, 208, 560-566.	2.0	53
31	Targeted Opioid Receptor Antagonists in the Treatment of Alcohol Use Disorders. CNS Drugs, 2013, 27, 777-787.	2.7	51
32	Anticonvulsants for the Treatment of Alcohol Withdrawal Syndrome and Alcohol Use Disorders. CNS Drugs, 2015, 29, 293-311.	2.7	51
33	Ketamine for depression: evidence, challenges and promise. World Psychiatry, 2015, 14, 348-350.	4.8	49
34	Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Molecular Psychiatry, 2018, 23, 1626-1631.	4.1	48
35	Characterizing the course of suicidal ideation response to ketamine. Journal of Affective Disorders, 2018, 241, 86-93.	2.0	44
36	DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS. Depression and Anxiety, 2014, 31, 297-307.	2.0	43

#	Article	IF	Citations
37	In Vivo Evidence for Î²2 Nicotinic Acetylcholine Receptor Subunit Upregulation in Smokers as Compared With Nonsmokers With Schizophrenia. Biological Psychiatry, 2014, 76, 495-502.	0.7	41
38	Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessiveâ€“compulsive disorder and a history of major depressive disorder. Journal of Psychopharmacology, 2013, 27, 651-654.	2.0	40
39	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectrums, 2013, 18, 231-241.	0.7	39
40	A functionally atypical amidating enzyme from the human parasite Schistosoma mansoni. FASEB Journal, 2004, 18, 114-121.	0.2	36
41	Reliability of 7T¹H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation. Journal of Magnetic Resonance Imaging, 2016, 43, 88-98.	1.9	35
42	Neurobiological aspects of suicide and suicide attempts in bipolar disorder. Translational Neuroscience, 2013, 4, 203-216.	0.7	34
43	Subanesthetic Dose Ketamine Does Not Induce an Affective Switch in Three Independent Samples of Treatment-Resistant Major Depression. Biological Psychiatry, 2013, 74, e23-e24.	0.7	33
44	Ketamineâ€™s Antidepressant Efficacy is Extended for at Least Four Weeks in Subjects with a Family History of an Alcohol Use Disorder. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	33
45	Pharmacologic Treatment of Dimensional Anxious Depression. primary care companion for CNS disorders, The, 2014, 16, .	0.2	32
46	Novel Glutamatergic Treatments for Severe Mood Disorders. Current Behavioral Neuroscience Reports, 2015, 2, 198-208.	0.6	29
47	Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. Acta Neuropsychiatrica, 2015, 27, 143-152.	1.0	28
48	Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. Molecular Psychiatry, 2014, 19, 962-964.	4.1	27
49	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. Journal of Affective Disorders, 2015, 172, 307-311.	2.0	27
50	Glial abnormalities in substance use disorders and depression: Does shared glutamatergic dysfunction contribute to comorbidity?. World Journal of Biological Psychiatry, 2014, 15, 2-16.	1.3	26
51	Neuroimaging in Alcohol and Drug Dependence. Current Behavioral Neuroscience Reports, 2014, 1, 45-54.	0.6	22
52	Subtypes of major depression in substance dependence. Addiction, 2009, 104, 1700-1709.	1.7	20
53	Riluzole likely lacks antidepressant efficacy in ketamine non-responders. Journal of Psychiatric Research, 2014, 58, 197-199.	1.5	20
54	Acute Stress Symptoms Do Not Worsen in Posttraumatic Stress Disorder and Abuse with a Single Subanesthetic Dose of Ketamine. Biological Psychiatry, 2013, 73, e37-e38.	0.7	17

#	Article	IF	Citations
55	Lithium and Valproate Levels Do Not Correlate with Ketamineâ€™s Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plasticity, 2015, 2015, 1-7.	1.0	17
56	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. Journal of Psychopharmacology, 2017, 31, 1570-1577.	2.0	17
57	Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. CNS Spectrums, 2013, 18, 242-251.	0.7	15
58	Biomarkers of ketamineâ€™s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology. Chronic Stress, 2021, 5, 247054702110142.	1.7	15
59	Baseline Vitamin B12 and Folate Levels Do Not Predict Improvement in Depression After a Single Infusion of Ketamine. Pharmacopsychiatry, 2014, 47, 141-144.	1.7	14
60	Biomarkers in mood disorders research: developing new and improved therapeutics. Revista De Psiquiatria Clinica, 2014, 41, 131-134.	0.6	11
61	A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder. Journal of Affective Disorders, 2015, 187, 241-244.	2.0	9
62	Neurophysiological Correlates and Differential Drug Response in Subjects With a Family History of an Alcohol Use Disorder. Chronic Stress, 2019, 3, 247054701986526.	1.7	6
63	Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability. Journal of Clinical Psychopharmacology, 2018, 38, 243-246.	0.7	3
64	330. A Principal Components Analysis of Depression and Anhedonia Scales: Illustrating the Heterogeneity of Depression. Biological Psychiatry, 2017, 81, S135.	0.7	2
65	1004. Clinical Predictors of an Antisuicidal Response to Ketamine. Biological Psychiatry, 2017, 81, S406.	0.7	1
66	296. Correlating Peripheral and Central Markers of Neuroinflammation to PET Imaging of Translocator Protein (TSPO). Biological Psychiatry, 2017, 81, S122.	0.7	0
67	1003. Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depression. Biological Psychiatry, 2017, 81, S405-S406.	0.7	0
68	199. Associations between Specific Dissociative Symptoms and Symptom Subsets and Anti-Depressant Response to Ketamine. Biological Psychiatry, 2017, 81, S82-S83.	0.7	0
69	Subanesthetic Dose of Ketamine Increases Mitochondrial Respiration in Human Neurons. Biological Psychiatry, 2020, 87, S340-S341.	0.7	0
70	Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior. , 2014, , 209-221.		0
71	Glutamate-based preclinical and clinical dysfunction and treatment in bipolar disorder. , 2022, , 215-252.		0